Delivery Order SPE2DB22D2206-SPE2DB24FGF39
Award Date
3/21/24
Potential Completion Date
4/11/24
Potential Value
$116K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Cencora, Inc.
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of the pharmaceutical product OCREVUS 300 MG/10 ML VIAL 10ML. The order has a potential value of $23,118.08 and a completion date of March 12, 2024. Amerisourcebergen Drug Corp is the prime contractor on this delivery order, which is issued under a larger indefinite delivery contract (IDC) the company...
The U.S. Defense Logistics Agency Troop Support Medical has awarded a $115,590.40 firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of OCREVUS 300 MG/10 ML VIAL 10ML. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp by DLA, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the provision of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty pharmaceutical product. The award has a ceiling value of $115,590.40 and a period of performance through April 10, 2024. This order is placed against an indefinite delivery contract (IDC) previously awarded to AmerisourceBergen Drug Corp by DLA, with a potential...
This is a $115,590.40 firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to the Corporate Office Division of Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The order is for 4,564,570,264 units of the drug OCREVUS 300 mg/10 ml vial. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 that Amerisourcebergen holds with the DLA Troop Support Medical to provide a comprehensive range of pharmaceutical...
The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract valued at $46,236.16 to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to provide 4565153318 OCREVUS 300 MG/10 ML VIAL 10ML. This order is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA, valued up to $999,999,999.00 through December 31, 2025, to deliver a broad range of pharmaceutical products and medical supplies in support of the Department of...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to the Corporate Office division of Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to provide OCREVUS 300 MG/10 ML VIAL 10ML. The $23,118.08 contract has a June 3, 2024 ultimate completion date. This award is made under Amerisourcebergen's larger $999,999,999.00 Indefinite Delivery Contract with DLA Troop Support Medical, which serves as the primary vehicle for the company to deliver a...
The Defense Logistics Agency (DLA) awarded a $34,677.12 firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of OCREVUS 300 MG/10 ML VIAL 10ML. This delivery order is part of a larger indefinite delivery contract (IDC) with a potential value of $999,999,999.00 that Amerisourcebergen Drug Corp holds with DLA to provide a comprehensive range of pharmaceutical products and medical supplies to military treatment...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation. The $115,590.40 contract is for the supply of OCREVUS 300 mg/10 ml vials to support military treatment programs and facilities. AmerisourceBergen Drug Corp is the prime contractor and has been awarded multiple previous contracts by DLA to provide pharmaceuticals and medical supplies to the Department of Defense. This delivery order...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $115,590.40 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide OCREVUS 300 mg/10 ml vials with a completion date of March 20, 2024. This contract is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp by DLA, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as...
Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, was awarded a firm fixed price delivery order contract by the Defense Logistics Agency (DLA) for the supply of OCREVUS 300 MG/10 ML VIAL 10ML. The total potential value of the contract is $115,590.40, with a completion date of March 12, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) awarded by DLA to Amerisourcebergen Drug Corp, which serves as the primary contract vehicle for the...